Table 7.
DNA based COVID-19 vaccine candidates in phase 2 and above
| DNA based Vaccine candidates currently in Phase 2/3 and above (Source: WHO as per 15th October 2021) | |||||
|---|---|---|---|---|---|
| Candidate | Dose | Schedule | Route of Administration | Phase | Developer |
| nCov vaccine | 3 | Day 0 + 28 + 56 | Intradermal |
Phase 3 CTRI/2020/07/026352 |
Zydus Cadila |
| AG0301-COVID19 | 2 | Day 0 + 14 | Intramuscular |
Phase 2/3 |
AnGes and Takara Bio and Osaka University |
| INO-4800 + electroporation | 2 | Day 0 + 28 | Intradermal |
Phase 2/3 |
Inovio Pharmaceuticals and International Vaccine Institute and Advaccine (Suzhou) Biopharmaceutical Co., Ltd |
| GX-19 N | 2 | Day 0 + 28 | Intramuscular |
Phase-2/3 |
Genexine consortium |